- Home
- ABT vs AZN Comparison
ABT vs AZN Comparison
Compare ABT & AZN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ABT
- AZN
- Stock Information
- Founded
- ABT 1888
- AZN 1992
- Country
- ABT United States
- AZN United Kingdom
- Employees
- ABT N/A
- AZN N/A
- Industry
- ABT Medical/Dental Instruments
- AZN Biotechnology: Pharmaceutical Preparations
- Sector
- ABT Health Care
- AZN Health Care
- Exchange
- ABT Nasdaq
- AZN Nasdaq
- Market Cap
- ABT 237.4B
- AZN 228.9B
- IPO Year
- ABT N/A
- AZN 1993
- Fundamental
- Price
- ABT $135.76
- AZN $70.14
- Analyst Decision
- ABT Buy
- AZN Strong Buy
- Analyst Count
- ABT 18
- AZN 3
- Target Price
- ABT $140.44
- AZN $95.00
- AVG Volume (30 Days)
- ABT 5.8M
- AZN 3.7M
- Earning Date
- ABT 07-17-2025
- AZN 07-24-2025
- Dividend Yield
- ABT 1.74%
- AZN 2.17%
- EPS Growth
- ABT 139.92
- AZN 22.71
- EPS
- ABT 7.70
- AZN 4.97
- Revenue
- ABT $42,344,000,000.00
- AZN $54,982,000,000.00
- Revenue This Year
- ABT $7.56
- AZN $9.56
- Revenue Next Year
- ABT $7.73
- AZN $6.09
- P/E Ratio
- ABT $17.62
- AZN $14.07
- Revenue Growth
- ABT 5.00
- AZN 15.48
- 52 Week Low
- ABT $99.71
- AZN $61.24
- 52 Week High
- ABT $141.23
- AZN $87.68
- Technical
- Relative Strength Index (RSI)
- ABT 55.08
- AZN 44.84
- Support Level
- ABT $132.71
- AZN $69.41
- Resistance Level
- ABT $136.26
- AZN $70.37
- Average True Range (ATR)
- ABT 2.47
- AZN 0.91
- MACD
- ABT 0.06
- AZN -0.35
- Stochastic Oscillator
- ABT 55.76
- AZN 12.23
About ABT Abbott Laboratories
Abbott manufactures and markets cardiovascular and diabetes devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, continuous glucose monitors, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
About AZN AstraZeneca PLC
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including oncology (about 40% of total revenue), cardiovascular, renal, and metabolic (25%), rare disease (17%), and respiratory and immunology (15%). The majority of sales comes from international markets, with the United States representing close to one third of its sales.